Improving Positioning in High-Dose Radiotherapy for Prostate Cancer: Safety and Visibility of Frequently Used Gold Fiducial Markers

Kuban, 2008, Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, 67, 10.1016/j.ijrobp.2007.06.054 Zietman, 2005, Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial, JAMA, 294, 1233, 10.1001/jama.294.10.1233 Dearnaley, 2007, Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial, Lancet Oncol, 8, 475, 10.1016/S1470-2045(07)70143-2 Peeters, 2006, Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy, J Clin Oncol, 24, 1990, 10.1200/JCO.2005.05.2530 Villeirs, 2011, Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients, Eur J Radiol, 77, 340, 10.1016/j.ejrad.2009.08.007 Arcangeli, 2010, A prospective Phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 78, 11, 10.1016/j.ijrobp.2009.07.1691 Cellini, 2002, Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning, Int J Radiat Oncol Biol Phys, 53, 595, 10.1016/S0360-3016(02)02795-5 De Meerleer, 2007, Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control, Radiother Oncol, 82, 160, 10.1016/j.radonc.2006.12.007 Artignan, 2004, Online ultrasound image guidance for radiotherapy of prostate cancer: Impact of image acquisition on prostate displacement, Int J Radiat Oncol Biol Phys, 59, 595, 10.1016/j.ijrobp.2004.01.043 Dehnad, 2003, Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation, Radiother Oncol, 67, 295, 10.1016/S0167-8140(03)00078-1 Van den Heuvel, 2003, Independent verification of ultrasound based image-guided radiation treatment, using electronic portal imaging and implanted gold markers, Med Phys, 30, 2878, 10.1118/1.1617354 Soete, 2007, X-ray-assisted positioning of patients treated by conformal arc radiotherapy for prostate cancer: Comparison of setup accuracy using implanted markers versus bony structures, Int J Radiat Oncol Biol Phys, 67, 823, 10.1016/j.ijrobp.2006.09.041 Pouliot, 2003, (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device, Int J Radiat Oncol Biol Phys, 56, 862, 10.1016/S0360-3016(03)00267-0 McNair, 2006, A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy, Int J Radiat Oncol Biol Phys, 65, 678, 10.1016/j.ijrobp.2006.01.022 Fonteyne, 2009, Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer, Radiother Oncol, 92, 42, 10.1016/j.radonc.2009.03.013 Fonteyne, 2007, Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity, Radiother Oncol, 84, 156, 10.1016/j.radonc.2007.06.013 Bland, 1995, Comparing methods of measurement: Why plotting difference against standard method is misleading, Lancet, 346, 1085, 10.1016/S0140-6736(95)91748-9 Fonteyne, 2009, Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer, Int J Radiat Oncol Biol Phys, 75, 1013, 10.1016/j.ijrobp.2008.12.047 Langenhuijsen, 2007, Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: Complication rate and risk factors, Int J Radiat Oncol Biol Phys, 69, 671, 10.1016/j.ijrobp.2007.04.009 Igdem, 2009, Implantation of fiducial markers for image guidance in prostate radiotherapy: Patient-reported toxicity, Br J Radiol, 82, 941, 10.1259/bjr/14201041 Kim, 2010, Risk factors for acute prostatitis after transrectal biopsy of the prostate, Korean J Urol, 51, 426, 10.4111/kju.2010.51.6.426 Ozden, 2009, Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy, Urology, 74, 119, 10.1016/j.urology.2008.12.067 Raaijmakers, 2002, Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program, Urology, 60, 826, 10.1016/S0090-4295(02)01958-1 Favaro, 2006, Morphometric and morphological features of the ventral prostate in rats submitted to chronic nicotine and alcohol treatment, Tissue Cell, 38, 311, 10.1016/j.tice.2006.08.002 Chiang, 2007, Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: A retrospective study of 1875 cases in taiwan, J Formos Med Assoc, 106, 929, 10.1016/S0929-6646(08)60063-7 Moman, 2010, Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life, Radiother Oncol, 96, 38, 10.1016/j.radonc.2010.02.027 Henry, 2004, Trans-perineal implantation of radio-opaque treatment verification markers into the prostate: An assessment of procedure related morbidity, patient acceptability and accuracy, Radiother Oncol, 73, 57, 10.1016/j.radonc.2004.08.007 Hara, 2008, Optimal approach for prostate cancer detection as initial biopsy: Prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy, Urology, 71, 191, 10.1016/j.urology.2007.09.029 Oldham, 2005, Cone-beam-CT guided radiation therapy: A model for on-line application, Radiother Oncol, 75, 271, 10.1016/j.radonc.2005.03.026 Moseley, 2007, Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate, Int J Radiat Oncol Biol Phys, 67, 942, 10.1016/j.ijrobp.2006.10.039 Barney, 2011, Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT), Int J Radiat Oncol Biol Phys, 80, 301, 10.1016/j.ijrobp.2010.06.007 Pucar, 2007, Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence, Int J Radiat Oncol Biol Phys, 69, 62, 10.1016/j.ijrobp.2007.03.065 Fonteyne, 2008, Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion, Int J Radiat Oncol Biol Phys, 72, 799, 10.1016/j.ijrobp.2008.01.040 Chow, 2006, Monte Carlo simulations of dose near a nonradioactive gold seed, Med Phys, 33, 4614, 10.1118/1.2388573 Eade, 2007, What dose of external-beam radiation is high enough for prostate cancer?, Int J Radiat Oncol Biol Phys, 68, 682, 10.1016/j.ijrobp.2007.01.008 Lim, 2009, Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer, Int J Radiat Oncol Biol Phys, 74, 1609, 10.1016/j.ijrobp.2009.02.076 Ceelen, 2009, Peritoneal minimal residual disease in colorectal cancer: Mechanisms, prevention, and treatment, Lancet Oncol, 10, 72, 10.1016/S1470-2045(08)70335-8 Mantovani, 2004, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, 25, 677, 10.1016/j.it.2004.09.015